A microcap biotech salves old wounds with positive PhII report on status epilepticus, but plenty of questions remain
The tiny microcap biotech Marinus saw its shares $MRNS rocket up after posting a positive summary of their mid-stage data for IV ganaxolone in treating drug-resistant cases of status epilepticus. And that at least temporarily helped heal some bad wounds left by the latest of several setbacks earlier in the year.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.